Oral Treatment Revolution: BioCryst Transforms Pediatric Hereditary Angioedema Care with New FDA-Approved Formulation

For decades, children battling hereditary angioedema (HAE) faced a challenging reality: preventing life-threatening angioedema attacks meant enduring regular intravenous infusions or subcutaneous injections. This barrier to preventive care has now…

Continue Reading Oral Treatment Revolution: BioCryst Transforms Pediatric Hereditary Angioedema Care with New FDA-Approved Formulation